^
Association details:
| Biomarker: | KDR overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Excerpt:
Among GBM patients...elevated hypoxia-inducible factor-2 alpha and VEGF receptor-2 levels were associated with poor survival.
DOI:
10.1093/neuonc/noq099
Trial ID:
